LATS1

Across TCGA pan-cancer cohorts, LATS1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LATS1 data layer compared with 25 for mass-spec protein and 13 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LATS1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LATS1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where LATS1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	1.000	0.316	.005	38	view →
HNSC	DFS	Tertile	All	1.000	0.912	.011	12	view →
LUAD	DFS	Median	II,III,IV	0.301	0.896	.012	5	view →
UCEC	OS	Median	III,IV	0.884	0.554	.045	4	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.836	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LATS1–CCRCC (DFS)

Open the CCRCC breakdown →